$RYAN

Conklin Michael sold $86K of RYAN

Conklin Michael (EVP & CHRO) sold 2,043 shares of RYAN SPECIALTY HOLDINGS, INC. (RYAN) at $42.26 on 2026-08-13.

Original reporting
SEC EDGAR · Conklin Michael
Published Aug 14, 2026, 9:24 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 9:42 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$RYAN
Neutral
medium confidence
Mentioned
$RYAN
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RYANNeutralLow
01

Why it matters

The disclosure updates the record of insider activity and may influence short-term sentiment, but it does not provide new operating or financial guidance.

02

Market read

Traders may monitor insider activity for sentiment, but this specific sale is unlikely to be a standalone catalyst.

03

What to watch

The filing does not indicate whether the sale was part of a broader planned program, nor does it provide any change in business outlook or financial performance.

Relevance 3/10Novelty 3/10Timing: Filed 2026-08-14 after-hours; reflects sale executed 2026-08-13.

Background

This is an SEC Form 4 insider transaction for RYAN Specialty Holdings, reported by an executive (EVP and CHRO).

Company-level read

Ticker impact

$RYANNeutralMedium confidence
Context

RYAN Specialty Holdings disclosed an EVP and CHRO open-market sale of 2,043 shares at $42.2633 on 2026-08-13 via Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment.

Evidence & confidence

Form 4 insider sales are common and this one lacks additional context (no earnings, guidance, or operational change). The absence of a stated 10b5-1 plan can raise attention, but the disclosed size ($86.3K) is typically not material enough to drive fundamentals.

Market effects

No sector-level signal; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification or tax needs, so the market may overreact to the lack of a stated 10b5-1 plan.

Key entities

  • RYAN Specialty Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Conklin Michael

    EVP & CHRO who sold 2,043 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RYANMedAI 8/10

Ryan Specialty posts Q2 revenue gain as E&S market slows

Ryan Specialty Holdings, Inc. reported second-quarter 2026 net commissions and fees of $902.7 million, up 7.4% year-over-year. Total revenue for the quarter reached $916.6 million, a 7.2% increase from $855.2 million a year earlier. Organic revenue growth came in at 6.7%, down from 7.1% in the prior-year period. The deceleration continues a trend across multiple quarters as the broader E&S market moderates.

$RYANMed

RYAN SPECIALTY HOLDINGS, INC. (RYAN): Results of Operations and Financial Condition

RYAN SPECIALTY HOLDINGS, INC. (RYAN) filed an SEC Form 8-K — Results of Operations and Financial Condition. 1 RYAN SPECIALTY REPORTS SECOND QUARTER 2026 RESULTS - Total Revenue grew 7.2% year-over-year to $916.6 million - - Organic Revenue Growth Rate* of 6.7% year-over-year - - Net Income of $108.4 million , or $0.33 per diluted share - - Adjusted EBITDAC* grew 6.0% year-over-year to